On May 1, 2026, Lunai Bioworks Inc. completed a merger with Neurobridge IP Holdings, issuing 8 shares of Series B Convertible Preferred Stock valued at $20 million to the stockholders of Neurobridge. This merger aimed to enhance Lunai's compliance with Nasdaq listing standards and included a patent portfolio of intellectual property related to neurological treatments.